JNJ-6640
JNJ-6640 is an inhibitor targeting mycobacterial PurF (the first enzyme in the de novo purine biosynthesis pathway) with potent anti-tuberculosis activity. JNJ-6640 exhibits bactericidal activity against Mycobacterium tuberculosis in vitro, with an MIC90 of 8.6 nM. JNJ-6640 disrupts de novo purine biosynthesis, inhibits M. tuberculosis DNA replication in vivo. JNJ-6640 exhibits anti-tuberculosis efficacy in acutely infected mice. JNJ-6640 can be used for the study of tuberculosis[1].
Product Specifications
UNSPSC
12352005
Target
Bacterial
Related Pathways
Anti-infection
Applications
COVID-19-immunoregulation
Field of Research
Infection
Smiles
CC1=NNC(OC2=C(F)C=NC(N3C[C@H](CC3)C4=CC=NC=C4)=N2)=C1
Molecular Formula
C17H17FN6O
Molecular Weight
340.35
References & Citations
[1]Lamprecht DA, et al. Targeting de novo purine biosynthesis for tuberculosis treatment. Nature. 2025 Aug;644 (8075) :214-220.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
![Mouse Monoclonal NCAM-1/CD56 Antibody (OTI1B9) [Alexa Fluor 750]](https://cdn.genprice.uk/genprice/uk/genprice5.webp)
Mouse Monoclonal NCAM-1/CD56 Antibody (OTI1B9) [Alexa Fluor 750]
Recombinant Human Group 10 secretory phospholipase A2 (PLA2G10)
Recombinant Human Group 10 secretory phospholipase A2 (PLA2G10)
Recombinant Human Group 10 secretory phospholipase A2 (PLA2G10)